Bio-Thera Ventures Outside China With European Bevacizumab Filing
Files BAT1706 Biosimilar Of Avastin With EMA; FDA Filing Coming Soon
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
You may also be interested in...
China’s Bio-Thera has struck a licensing deal with Biomm that will give the Brazilian company exclusive rights to market the BAT1706 bevacizumab biosimilar in its home market.
China’s Bio-Thera solutions has announced the start of Phase I trials for its ustekinumab biosimilar. The project is one among several potential rivals to Stelara in the works from a host of developers.
Bio-Thera is collaborating with BeiGene for BAT1706, a biosimilar to Avastin (bevacizumab), to develop, manufacture and commercialize the product in Greater China.